Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$121.92 USD

121.92
1,346,913

-3.22 (-2.57%)

Updated Jul 17, 2024 01:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novavax (NVAX) Down as EU Adds Side Effects to COVID Jab Label

by Zacks Equity Research

The administration of Novavax's (NVAX) COVID-19 vaccine leads to some cases of severe allergic reactions as well as skin problems, per a safety update issued by the EMA.

Novavax's (NVAX) Protein-Based COVID Jab Gets EUA in the US

by Zacks Equity Research

Following the grant of emergency use authorization by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in the United States.

Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study

by Zacks Equity Research

Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.

Novavax (NVAX) Inks COVID Jab Supply Deal With US Government

by Zacks Equity Research

Novavax (NVAX) inks a deal with the US government to supply 3.2 million doses of COVID shot. But the deal will be effective only if the vaccine gets EUA from the FDA. It also needs CDC recommendation.

Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5

by Zacks Equity Research

Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.

Moderna (MRNA) Stock Moves -0.55%: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $175.26, moving -0.55% from the previous trading session.

PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.

Stock Market News for Jul 11, 2022

by Zacks Equity Research

Wall Street had a mixed day on Friday in a choppy session of trading.

Company News for Jul 8, 2022

by Zacks Equity Research

Companies In The News Are: GME, MRNA, LCID, SLP.

Novavax (NVAX) Stock Rallies 26.8% in a Month: Here's Why

by Zacks Equity Research

FDA's advisory committee supports granting authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. The vaccine also receives authorization for use in adolescents in Europe.

Novavax (NVAX) COVID Jab Receives EU Nod for Adolescents

by Zacks Equity Research

Novavax (NVAX) obtains EU approval for its Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17.

Can Moderna (MRNA) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Analyst Blog Highlights Pfizer, BioNTec and Moderna

by Zacks Equity Research

Pfizer, BioNTec and Moderna are part of Zacks Analyst top Blog.

Sundeep Ganoria headshot

FDA Recommends Adding New Omicron Subvariants to COVID Boosters

by Sundeep Ganoria

In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.

Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.

The Chef's Warehouse and AZEK have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

The Chef's Warehouse and AZEK are part of as Zacks Bull and Bear of the Day article.

Kinjel Shah headshot

FDA Panel Recommends Modifying COVID Jabs to Target Omicron

by Kinjel Shah

The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $145.36, marking a +0.76% move from the previous day.

Pfizer's (PFE) Omicron-Based COVID Shot Betters Immune Response

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.

Novavax (NVAX) Up as EMA Recommends COVID Jab for Adolescents

by Zacks Equity Research

EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.

Kinjel Shah headshot

Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates

by Kinjel Shah

The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).

Moderna (MRNA) Reveals New Data on Bivalent COVID Booster

by Zacks Equity Research

Moderna's (MRNA) bivalent COVID booster candidate exhibits a greater than a 5-fold boost in antibody responses against the Omicron subvariants BA.4 and BA.5 in a phase II/III study.

Company News for Jun 23, 2022

by Zacks Equity Research

Companies in The News Are: MRNA, KFY, XOM, WGO

Biotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More

by Zacks Equity Research

Regulatory and other updates from Moderna (MRNA) and Acer (ACER) are a few key highlights from the biotech sector during the past week.

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $129.99, marking a +1.53% move from the previous day.